EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Thrombotic Markers in Plasma as Predictors of Response in Rheumatoid Arthritis Patients Treated with Baricitinib – Pilot Observation

Anna Felis-Giemza iD, Kornelia Chmurzynska iD, Jakub Wronski iD, Paulina Klimek iD, Anna Kornatka iD, Wlodzimierz Maslinski iD, Marzena Ciechomska iD, Magdalena Massalska iD

Archivum Immunologiae et Therapiae Experimentalis · 2025

DOI: 10.2478/aite-2025-0010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archivum Immunologiae et Therapiae Experimentalis, 2025. Verfasst von Anna Felis-Giemza und 7 weiteren Autor:innen. Beteiligte Einrichtung: Biologic Therapy Center and Central Clinical Laboratory, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Purines, Azetidines, Sulfonamides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Both disease and treatment carry the risk of thrombotic events in patients with rheumatoid arthritis (RA). This pilot study aimed to assess changes in thrombotic markers in plasma and their potential role as predictors of response during early baricitinib treatment. The concentrations of antithrombin III (ATIII) activity, D-dimer (DD), fibrinogen, and homocysteine (HCY) were evaluated in RA subjects before and 3 months after the treatment. At baseline, the RA group had higher DD (1472.3 ± 349.2) and fibrinogen (410.4 ± 29.5) compared with healthy controls (HC; 450.3 ± 54.5; p = 0.0002 and 334.9 ± 19.2; p = 0.04, respectively). with no differences in ATIII and HCY. After 3 months, we observed a significant increase in HCY (10.7 ± 0.6 vs. 9.1 ± 0.5; p = 0.018) and ATIII (119.7 ± 2.7 vs . 110.4 ± 3.2; p = 0.004), the latter correlated negatively with disease activity score 28 (DAS28; r = −0686, p < 0.002). After 3 months of baricitinib therapy, the patients were divided into moderate responders (MR) and good responders (GR) groups according to EULAR criteria. At baseline, MR had higher DD (1639.2 ± 550.5 vs . 450.3 ± 54.5; p < 0.0001) and lower ATIII (105.3 ± 3.6 vs . 115.1 ± 2.7; p = 0.043) compared with HC. Thrombotic parameters in the first 3 months of baricitinib treatment were mostly in line with current findings concerning the RA population. Increased levels of DD together with low ATIII concentrations seem to predispose to a moderate response to baricitinib treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidPurinesAzetidinesSulfonamidesThrombosisPyrazolesAntirheumatic AgentsHumansMaleFemalePilot ProjectsMiddle AgedBiomarkersFibrinogenAgedFibrin Fibrinogen Degradation ProductsAdultAntithrombin IIITreatment Outcome

Stichwörter der Autor:innen

Antithrombin IIIBaricitinibCardiometabolic risk biomarkersFibrinogenHomocysteinRheumatoid arthritis

Substanzen

baricitinibPurinesAzetidinesSulfonamidesBiomarkersPyrazolesFibrinogenFibrin Fibrinogen Degradation Productsfibrin fragment DAntithrombin III

Autor:innen und Institutionen

  • Biologic Therapy Center and Central Clinical Laboratory, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
  • Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
  • Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
  • Central Clinical Laboratory, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
  • Department of Pathophysiology and Immunology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.

ORCID-Profile: Anna Felis-Giemza, Kornelia Chmurzynska, Jakub Wronski, Paulina Klimek, Anna Kornatka, Wlodzimierz Maslinski, Marzena Ciechomska, Magdalena Massalska

Zitieren

APA

Felis-Giemza, A., Chmurzynska, K., Wronski, J., Klimek, P., Kornatka, A., Maslinski, W., Ciechomska, M., & Massalska, M. (2025). Thrombotic Markers in Plasma as Predictors of Response in Rheumatoid Arthritis Patients Treated with Baricitinib – Pilot Observation. Archivum Immunologiae et Therapiae Experimentalis. https://doi.org/10.2478/aite-2025-0010

Vancouver

Felis-Giemza A, Chmurzynska K, Wronski J, Klimek P, Kornatka A, Maslinski W, et al. Thrombotic Markers in Plasma as Predictors of Response in Rheumatoid Arthritis Patients Treated with Baricitinib – Pilot Observation. Archivum Immunologiae et Therapiae Experimentalis. 2025. doi:10.2478/aite-2025-0010

BibTeX
@article{FelisGiemza2025,
  author = {Felis-Giemza, Anna and Chmurzynska, Kornelia and Wronski, Jakub and Klimek, Paulina and Kornatka, Anna and Maslinski, Wlodzimierz and Ciechomska, Marzena and Massalska, Magdalena},
  title = {Thrombotic Markers in Plasma as Predictors of Response in Rheumatoid Arthritis Patients Treated with Baricitinib – Pilot Observation},
  journal = {Archivum Immunologiae et Therapiae Experimentalis},
  year = {2025},
  doi = {10.2478/aite-2025-0010}
}
Kostenlos starten →